Literature DB >> 8496390

Overexpression of p53 protein in Barrett's syndrome with malignant transformation.

J F Fléjou1, F Potet, F Muzeau, F Le Pelletier, F Fékété, D Hénin.   

Abstract

AIMS: To study the overexpression of p53 protein in Barrett's oesophagus with adenocarcinoma, and to correlate this expression with the pathological features of Barrett's syndrome.
METHODS: Immunohistochemical staining was performed on frozen sections with a monoclonal antibody directed against wild type and mutated p53 protein (Pab 1801). Eleven cases of Barrett's adenocarcinoma were studied, seven of which had extensive sampling of benign Barrett's mucosa.
RESULTS: Eight of 11 adenocarcinomas overexpressed the p53 protein. Both early and advanced tumours were positive. In Barrett's mucosa around the p53 positive tumours, high grade dysplasia was positive; low grade dysplasia and non-dysplastic mucosa were negative.
CONCLUSIONS: P53 gene mutation with ensuing p53 protein overexpression is a common feature of Barrett's adenocarcinoma, both at early and advanced stages. This mutation appears as a relatively late event during the neoplastic transformation of Barrett's oesophagus.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8496390      PMCID: PMC501213          DOI: 10.1136/jcp.46.4.330

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  26 in total

Review 1.  Barrett's oesophagus.

Authors:  F Potet; V Duchatelle
Journal:  Curr Top Pathol       Date:  1990

2.  Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression.

Authors:  L Banks; G Matlashewski; L Crawford
Journal:  Eur J Biochem       Date:  1986-09-15

3.  Endoscopic biopsy can detect high-grade dysplasia or early adenocarcinoma in Barrett's esophagus without grossly recognizable neoplastic lesions.

Authors:  B J Reid; W M Weinstein; K J Lewin; R C Haggitt; G VanDeventer; L DenBesten; C E Rubin
Journal:  Gastroenterology       Date:  1988-01       Impact factor: 22.682

4.  Management of high-grade dysplasia in Barrett's esophagus.

Authors:  S L Palley; R E Sampliner; H S Garewal
Journal:  J Clin Gastroenterol       Date:  1989-08       Impact factor: 3.062

5.  Localization of gene for human p53 tumour antigen to band 17p13.

Authors:  M Isobe; B S Emanuel; D Givol; M Oren; C M Croce
Journal:  Nature       Date:  1986 Mar 6-12       Impact factor: 49.962

6.  Mutations in the p53 gene occur in diverse human tumour types.

Authors:  J M Nigro; S J Baker; A C Preisinger; J M Jessup; R Hostetter; K Cleary; S H Bigner; N Davidson; S Baylin; P Devilee
Journal:  Nature       Date:  1989-12-07       Impact factor: 49.962

7.  Barrett's esophagus: development of dysplasia and adenocarcinoma.

Authors:  W Hameeteman; G N Tytgat; H J Houthoff; J G van den Tweel
Journal:  Gastroenterology       Date:  1989-05       Impact factor: 22.682

8.  P53 expression in breast cancer.

Authors:  G Cattoretti; F Rilke; S Andreola; L D'Amato; D Delia
Journal:  Int J Cancer       Date:  1988-02-15       Impact factor: 7.396

9.  The relationship between columnar epithelial dysplasia and invasive adenocarcinoma arising in Barrett's esophagus.

Authors:  S R Hamilton; R R Smith
Journal:  Am J Clin Pathol       Date:  1987-03       Impact factor: 2.493

10.  Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas.

Authors:  S J Baker; E R Fearon; J M Nigro; S R Hamilton; A C Preisinger; J M Jessup; P vanTuinen; D H Ledbetter; D F Barker; Y Nakamura; R White; B Vogelstein
Journal:  Science       Date:  1989-04-14       Impact factor: 47.728

View more
  14 in total

1.  Foveolar hyperplasia following partial gastrectomy results from expansion of surface mucous cell compartment.

Authors:  G S Ray; M W Jackson; J R Goldenring
Journal:  Dig Dis Sci       Date:  1996-10       Impact factor: 3.199

Review 2.  Role of p53 assessment in management of Barrett's esophagus.

Authors:  A K Kubba; N A Poole; A Watson
Journal:  Dig Dis Sci       Date:  1999-04       Impact factor: 3.199

3.  Adenocarcinoma arising in Barrett's oesophagus: evidence for the participation of p53 dysfunction in the dysplasia/carcinoma sequence.

Authors:  R H Hardwick; N A Shepherd; M Moorghen; P V Newcomb; D Alderson
Journal:  Gut       Date:  1994-06       Impact factor: 23.059

4.  Expression of p53, PCNA, and C-erbB-2 in Barrett's metaplasia and adenocarcinoma.

Authors:  R Kim; M R Clarke; M F Melhem; M A Young; M M Vanbibber; A V Safatle-Ribeiro; U Ribeiro; J C Reynolds
Journal:  Dig Dis Sci       Date:  1997-12       Impact factor: 3.199

5.  p53 protein accumulation predicts malignant progression in Barrett's metaplasia: a prospective study of 275 patients.

Authors:  Mamoun Younes; Keith Brown; Gregory Y Lauwers; Gulchin Ergun; Frank Meriano; A Carl Schmulen; Alberto Barroso; Atilla Ertan
Journal:  Histopathology       Date:  2017-04-11       Impact factor: 5.087

Review 6.  Barrett's esophagus. The significance of p53 in clinical practice.

Authors:  A P Ireland; G W Clark; T R DeMeester
Journal:  Ann Surg       Date:  1997-01       Impact factor: 12.969

7.  p53 alterations in oesophageal cancer: association with clinicopathological features, risk factors, and survival.

Authors:  A G Casson; M Tammemagi; S Eskandarian; M Redston; J McLaughlin; H Ozcelik
Journal:  Mol Pathol       Date:  1998-04

8.  Expression of the p53 homologue p63alpha and DeltaNp63alpha in the neoplastic sequence of Barrett's oesophagus: correlation with morphology and p53 protein.

Authors:  P A Hall; A C Woodman; S J Campbell; N A Shepherd
Journal:  Gut       Date:  2001-11       Impact factor: 23.059

Review 9.  Barrett's esophagus: model of neoplastic progression.

Authors:  Stig Ramel
Journal:  World J Surg       Date:  2003-08-18       Impact factor: 3.352

10.  The significance of c-erb B-2 and p53 immunoreactivity in patients with adenocarcinoma of the esophagus.

Authors:  F G Duhaylongsod; M R Gottfried; J D Iglehart; A L Vaughn; W G Wolfe
Journal:  Ann Surg       Date:  1995-06       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.